181 related articles for article (PubMed ID: 35115601)
1. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Fajardo-Robledo NS; Jacobo-Cuevas H; Perez-Guerrero EE; Corona-Sanchez EG; Saldaña-Cruz AM; Romero-Tejeda EM; Rodriguez-Jimenez NA; Totsuka-Sutto SE; Lopez-Roa RI; Ponce-Guarneros JM; Alcaraz-Lopez MF; Cerpa-Cruz S; Muñoz-Valle JF; Cardona-Muñoz EG; Gonzalez-Lopez L; Gamez-Nava JI;
Sci Rep; 2022 Feb; 12(1):1877. PubMed ID: 35115601
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Bergner R; Peters L; Schmitt V; Löffler C
Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.
Ren LM; Li R; Chen LN; Zhu P; Gu F; Sun LY; Zhao JX; Liu XY; Guo JL; Bi LQ; Hao YJ; Zhang ZL; Mei YF; Zhang ZY; Liu HX; Li XF; Luo Y; Fang YF; Li ZG; Su Y
Int J Rheum Dis; 2016 Jul; 19(7):651-7. PubMed ID: 26268935
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice.
Sakellariou GT; Sayegh FE; Kapetanos GA; Berberidis C
Clin Rheumatol; 2012 Jan; 31(1):163-7. PubMed ID: 21904814
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Khurana D; Kaur G; Sendhil Kumaran M; Choudhary R; Ashraf R; Thakur V
Clin Exp Dermatol; 2021 Jan; 46(1):166-169. PubMed ID: 32557734
[No Abstract] [Full Text] [Related]
11. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P
Clin Rheumatol; 2020 Sep; 39(9):2593-2601. PubMed ID: 32166429
[TBL] [Abstract][Full Text] [Related]
13. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
Shin K; Baek HJ; Kang YM; Cha HS; Kang SW; Park SH; Jun JB; Lee YJ; Choi IA; Song YW
Int J Rheum Dis; 2019 Jun; 22(6):1115-1122. PubMed ID: 30861334
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
Chan V; Charles BG; Tett SE
Br J Clin Pharmacol; 2005 Sep; 60(3):257-64. PubMed ID: 16120064
[TBL] [Abstract][Full Text] [Related]
16. The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients.
Shahin AA; El-Agha S; El-Azkalany GS
Clin Rheumatol; 2014 Jul; 33(7):925-30. PubMed ID: 24647977
[TBL] [Abstract][Full Text] [Related]
17. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
18. Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.
Zhu H; Li R; Da Z; Bi L; Li X; Li Y; Liu C; Zhang F; Li Z; Liu X; Zhang Z; Sun L; Wang Y; Zhang W; Jiang Q; Chen J; Chen Q; Li Z; Wu L; Qi W; Xu J; Cui X; Wang X; Li L; Leng X; Wang G; Zhao D; Jiang L; He D; Liu X; Li L; Fang Y; Huang C; Wu H; Hu S; Li Q; Song H; Xiao W; Gong L; Zhang L; Li X; Li Z; Su Y
Clin Rheumatol; 2018 Mar; 37(3):597-605. PubMed ID: 29116543
[TBL] [Abstract][Full Text] [Related]
19. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.
Li R; Zhao JX; Su Y; He J; Chen LN; Gu F; Zhao C; Deng XR; Zhou W; Hao YJ; Xue Y; Liu HX; Zhao Y; Zou QH; Liu XY; Zhu P; Sun LY; Zhang ZL; Zou HJ; Li XF; Liu Y; Fang YF; Keystone E; McInnes IB; Li ZG
Medicine (Baltimore); 2016 Jul; 95(28):e3968. PubMed ID: 27428186
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Katayama K; Matsuno T
Mod Rheumatol; 2009; 19(5):513-21. PubMed ID: 19603251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
